相关实验视频

Updated: May 10, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

释放CBD的抗糖尿病潜力:体内临床前研究

Elena Rafailovska¹, Elona Xhemaili², Zorica Naumovska³

¹Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, Arhimedova 3, 1000 Skopje, North Macedonia.

Pharmaceuticals (Basel, Switzerland)

|April 26, 2025

概括

大麻 (CBD) 通过改善糖尿病大鼠的葡萄糖代谢和胰岛素水平,在治疗糖尿病方面表现有前途. 50毫克/千克的剂量显示出最显著的抗糖尿病作用,强调了CBD的作用.

科学领域:

内分泌学在内分泌学.
代谢障碍代谢障碍代谢障碍
药理学药理学是指药理学的学科.

背景情况:

糖尿病是一种重大的全球健康挑战.
Cannabidiol (CBD) 正在研究其潜在的抗糖尿病特性,包括改善胰岛素敏感性.
CBD对葡萄糖代谢的确切影响需要进一步阐明.

研究的目的:

在糖尿病的小鼠模型中,研究大麻素 (CBD) 对血糖,胰岛素水平和肝脏碳水化合物代谢的剂量依赖作用.
为了比较CBD的胃内与腹腔内给药的疗效.

主要方法:

在健康的老鼠中进行了口服葡萄糖耐受性测试 (OGTT),以评估CBD的给药途径.
糖尿病老鼠接受了胃内CBD (25,50,100毫克/公斤) 或甲胺 (70毫克/公斤) 八天.
分析包括血糖,胰岛素,脂质概况和关键碳水化合物代谢酶.

主要成果:

胃内CBD,特别是50mg/kg,在OGTT中降低了曲线下的血糖面积 (AUC),而腹腔内给药是无效的.
在糖尿病大鼠中,CBD (25和50毫克/千克) 降低了血糖和增加了胰岛素水平,50毫克/千克的剂量显示出最明显的效应.
参与葡萄糖代谢的CBD调节的肝酶,包括抑制葡萄糖-6-酸酶和葡萄糖原酶,以及改变葡萄糖-6-酸盐和酸酶活性.

结论:

大麻具有显著的抗糖尿病潜力,特别是在50毫克/千克的剂量下,在老鼠模型中.
CBD的治疗效果与其调节葡萄糖代谢和影响胰岛素调节的能力有关.
此外,CBD还对脂质资料产生积极影响,降低三糖醇,增加高密度脂质胆固醇.

关键词:

一个OGTT,一个OGTT.在Cannabidiol中使用.在糖尿病中,糖尿病是血糖类的.肝脏碳水化合物代谢胰岛素敏感性胰岛素敏感性实验室动物实验室动物

更多相关视频

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

相关概念视频

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...